13.64
0.25 (1.87%)
| Penutupan Terdahulu | 13.39 |
| Buka | 13.50 |
| Jumlah Dagangan | 1,454,573 |
| Purata Dagangan (3B) | 1,940,485 |
| Modal Pasaran | 1,326,069,760 |
| Harga / Buku (P/B) | 9.77 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -0.750 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 9.89% |
| Nisbah Semasa (MRQ) | 7.27 |
| Aliran Tunai Operasi (OCF TTM) | -91.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -96.27 M |
| Pulangan Atas Aset (ROA TTM) | -25.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -37.06% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Mind Medicine (MindMed) Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.10 |
|
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.85% |
| % Dimiliki oleh Institusi | 55.15% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 61.00 (Jones Trading, 347.21%) | Beli |
| Median | 26.50 (94.28%) | |
| Rendah | 20.00 (RBC Capital, 46.63%) | Beli |
| Purata | 33.50 (145.60%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 12.42 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jones Trading | 23 Dec 2025 | 61.00 (347.21%) | Beli | 14.02 |
| Canaccord Genuity | 07 Nov 2025 | 25.00 (83.28%) | Beli | 11.70 |
| RBC Capital | 07 Nov 2025 | 20.00 (46.63%) | Beli | 11.70 |
| Needham | 13 Oct 2025 | 28.00 (105.28%) | Beli | 12.25 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BARROW ROBERT | - | 13.06 | -25,791 | -336,830 |
| KARLIN DANIEL | - | 13.06 | -5,600 | -73,136 |
| SULLIVAN MARK | - | 13.06 | -11,276 | -147,265 |
| Jumlah Keseluruhan Kuantiti Bersih | -42,667 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -557,231 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 13.06 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SULLIVAN MARK | Pegawai | 26 Dec 2025 | Jual automatik (-) | 11,276 | 13.06 | 147,265 |
| BARROW ROBERT | Pegawai | 26 Dec 2025 | Jual automatik (-) | 25,791 | 13.06 | 336,830 |
| KARLIN DANIEL | Pegawai | 26 Dec 2025 | Jual automatik (-) | 5,600 | 13.06 | 73,136 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |